|
30 Dec 2019 |
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
|
|
30 Dec 2019 |
Commencement of phase 1 trial for AZD0466 utilising DEP
|
|
30 Dec 2019 |
Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
|
|
26 Dec 2019 |
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
|
|
26 Dec 2019 |
Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs
|
|
24 Dec 2019 |
Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults
|
|
23 Dec 2019 |
Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder
|
|
23 Dec 2019 |
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
|
|
23 Dec 2019 |
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND
|
|
23 Dec 2019 |
Polaryx Therapeutics Submits Investigational New Drug Application to the U.S. FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis With PLX-200
|
|
23 Dec 2019 |
SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma
|
|
23 Dec 2019 |
U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients
|
|
23 Dec 2019 |
Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
|
|
23 Dec 2019 |
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection
|
|
23 Dec 2019 |
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
|
|
23 Dec 2019 |
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint
|
|
23 Dec 2019 |
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
|
21 Dec 2019 |
VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide
|
|
21 Dec 2019 |
Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
|
|
21 Dec 2019 |
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
|
|
20 Dec 2019 |
MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis
|
|
20 Dec 2019 |
Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI
|
|
20 Dec 2019 |
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
|
|
20 Dec 2019 |
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
|
|
20 Dec 2019 |
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018
|
